Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | FABP4 | P15090 | 8/20 | 0.72 |
| ▸ | PTGIR | P43119 | 8/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP3 | P05413 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640642 | 1.00 | KDM4E (1.00) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19163857 | 0.92 | KDM4E (0.85) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9428515 | 0.90 | MEN1 (0.82) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9593239 | 0.89 | ALDH1A1 (0.80) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9428853 | 0.86 | KDM4E (0.76) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL8066970 | 0.85 | FABP4 (0.79) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL14698129 | 0.85 | KDM4E (0.74) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9594904 | 0.84 | KDM4E (0.72) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9428317 | 0.84 | FABP4 (1.00) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30398835 | 0.84 | FABP4 (1.00) | KDM4EMEN1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381243-B2 | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof | RIGSHOSPITALET (DK) | 2016-07-05 | — | — | US | claimed |
| US-20150057325-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | RIGSHOSPITALET (DK) | 2015-02-26 | — | — | US | claimed |
| EP-2834642-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | Rigshospitalet (DK) | 2015-02-11 | — | — | EP | claimed |
| US-8877710-B2 | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof | RIGHOSPITALET (DK) | 2014-11-04 | — | — | US | claimed |
| US-20140322207-A1 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | ENDOTHEL PHARMA APS (DK) | 2014-10-30 | — | — | US | claimed |
| EP-2699243-A1 | PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE | Rigshospitalet (DK) | 2014-02-26 | — | — | EP | claimed |
| US-20140044797-A1 | PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE | RIGSHOSPITALET (DK) | 2014-02-13 | — | — | US | claimed |
| US-20130261177-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | RIGSHOSPITALET (DK) | 2013-10-03 | — | — | US | claimed |
| WO-2013143548-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | RIGSHOSPITALET (DK) | 2013-10-03 | — | — | WO | claimed |
| EP-2622354-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | Rigshospitalet (DK) | 2013-08-07 | — | — | EP | claimed |
| EP-2563369-A2 | METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF | Thrombologic APS (DK) | 2013-03-06 | — | — | EP | claimed |
| US-20130040898-A1 | METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF | THROMBOLOGIC APS (DK) | 2013-02-14 | — | — | US | claimed |
| WO-2012143012-A1 | PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE | RIGSHOSPITALET (DK) | 2012-10-26 | — | — | WO | claimed |
| WO-2012041334-A1 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST | RIGSHOSPITALET (DK) | 2012-04-05 | — | — | WO | claimed |
| EP-2384196-A2 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | Thrombologic APS (DK) | 2011-11-09 | — | — | EP | claimed |
| US-20110268732-A1 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | THROMBOLOGIC APS (DK) | 2011-11-03 | — | — | US | claimed |
| WO-2011134478-A2 | METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF | THROMBOLOGIC APS (DK) | 2011-11-03 | — | — | WO | claimed |
| WO-2010075861-A2 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | THROMBOLOGIC APS (DK) | 2010-07-08 | — | — | WO | claimed |
| US-11857537-B2 | Use of prostacyclin antagonists for treating ocular surface nociception | JENIVISION INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2010075861-A2 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | THROMBOLOGIC APS (DK) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857537-B2 | Use of prostacyclin antagonists for treating ocular surface nociception | PTGIR, PTGIS, TRPA1 | KDM4E 4665/4885MEN1 4843/4885ALDH1A1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.